Menu
← Oncology Approval Tracker
FDA DECISION ·
Adcetris + AVE-PC
brentuximab vedotin plus doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide · Seagen
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Children age two or older with previously untreated high-risk classical Hodgkin lymphoma receiving brentuximab vedotin with the AVE-PC regimen.
LAMPGEN ANALYSIS
Why it matters
This adds a CD30-directed antibody-drug conjugate to frontline therapy for a defined high-risk pediatric population.
What research teams should watch
Confirm the pediatric risk category and coordinate chemotherapy administration and neuropathy monitoring.
PRIMARY RECORDS